Association of sclerostin with cardiovascular events and mortality in dialysis patients

References

• Komatsu M, Okazaki M, Tsuchiya K, et al. Aortic arch calcification predicts cardiovascular and all-cause mortality in maintenance hemodialysis patients. Kidney Blood Press Res. 2014;39(6):658–667.
   PubMed Web of Science ®Google Scholar
• Iwasa Y, Otsubo S, Nomoto K, et al. Prevalence of intracranial artery calcification in hemodialysis patients—a case-control study. Int Urol Nephrol. 2012;44(4):1223–1228.
   PubMed Web of Science ®Google Scholar
• Cano-Megías M, Guisado-Vasco P, Bouarich H, et al. Coronary calcification as a predictor of cardiovascular mortality in advanced chronic kidney disease: a prospective long-term follow-up study. BMC Nephrol. 2019;20(1):188.
   PubMedGoogle Scholar
• Ammirati AL, Dalboni MA, Cendoroglo M, et al. The progression and impact of vascular calcification in peritoneal dialysis patients. Perit Dial Int. 2007;27(3):340–346.
   PubMed Web of Science ®Google Scholar
• Gauthier-Bastien A, Ung RV, Larivière R, et al. Vascular remodeling and media calcification increases arterial stiffness in chronic kidney disease. Clin Exp Hypertens. 2014;36(3):173–180.
   PubMed Web of Science ®Google Scholar
• Kramann R, Kunter U, Brandenburg VM, et al. Osteogenesis of heterotopically transplanted mesenchymal stromal cells in rat models of chronic kidney disease. J Bone Miner Res. 2013;28(12):2523–2534.
   PubMed Web of Science ®Google Scholar
• Mesquita M, Demulder A, Damry N, et al. Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. Clin Chem Lab Med. 2009;47(3):339–346.
   PubMed Web of Science ®Google Scholar
• Nishiura R, Fujimoto S, Sato Y, et al. Elevated osteoprotegerin levels predict cardiovascular events in new hemodialysis patients. Am J Nephrol. 2009;29(3):257–263.
   PubMed Web of Science ®Google Scholar
• Shantouf R, Kovesdy CP, Kim Y, et al. Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. CJASN. 2009;4(6):1106–1114.
   PubMed Web of Science ®Google Scholar
• Gaudio A, Privitera F, Battaglia K, et al. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97(10):3744–3750.
   PubMed Web of Science ®Google Scholar
• Martínez-Moreno JM, Muñoz-Castañeda JR, Herencia C, et al. In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/β-catenin activation. Am J Physiol Renal Physiol. 2012;303(8):F1136–44.
   PubMed Web of Science ®Google Scholar
• De Maré A, Maudsley S, Azmi A, et al. Sclerostin as regulatory molecule in vascular media calcification and the bone-vascular axis. Toxins (Basel). 2019;11(7) 428.
   Web of Science ®Google Scholar
• Li M, Zhou H, Yang M, et al. Relationship between serum sclerostin, vascular sclerostin expression and vascular calcification assessed by different methods in ESRD patients eligible for renal transplantation: a cross-sectional study. Int Urol Nephrol. 2019;51(2):311–323.
   PubMed Web of Science ®Google Scholar
• Morena M, Jaussent I, Dupuy AM, et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant. 2015;30(8):1345–1356.
   PubMed Web of Science ®Google Scholar
• Yang CY, Chang ZF, Chau YP, et al. Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications. Nephrol Dial Transplant. 2015;30(8):1356–1363.
   PubMed Web of Science ®Google Scholar
• Delanaye P, Krzesinski JM, Warling X, et al. Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract. 2014;128(1–2):127–134.
   PubMedGoogle Scholar
• Drechsler C, Evenepoel P, Vervloet MG, et al.; for the NECOSAD Study Group. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant. 2015;30(2):288–293.
   PubMed Web of Science ®Google Scholar
• Kirkpantur A, Balci M, Turkvatan A, et al. Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients. Nefrologia. 2016;36(1):24–32.
   PubMed Web of Science ®Google Scholar
• Hoek FJ, Korevaar JC, Dekker FW, et al. Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level. Nephrol Dial Transplant. 2007;22(6):1633–1638.
   PubMed Web of Science ®Google Scholar
• Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15(4):827–832.
   PubMed Web of Science ®Google Scholar
• Jean G, Chazot C, Bresson E, et al. High serum sclerostin levels are associated with a better outcome in haemodialysis patients. Nephron. 2016;132(3):181–190.
   PubMed Web of Science ®Google Scholar
• Gonçalves FL, Elias RM, dos Reis LM, et al. Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol. 2014;15(1):190.
   PubMedGoogle Scholar
• Kanbay M, Solak Y, Siriopol D, et al. Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. Int Urol Nephrol. 2016;48(12):2029–2042.
   PubMed Web of Science ®Google Scholar
• Nowak A, Artunc F, Serra AL, et al. Sclerostin quo vadis? – Is this a useful long-term mortality parameter in prevalent hemodialysis patients? Kidney Blood Press Res. 2015;40(3):266–276.
   PubMed Web of Science ®Google Scholar
• Stavrinou E, Sarafidis PA, Koumaras C, et al. Increased sclerostin, but not Dickkopf-1 protein, is associated with elevated pulse wave velocity in hemodialysis subjects. Kidney Blood Press Res. 2019;44(4):679–689.
   PubMed Web of Science ®Google Scholar
• de Oliveira RA, Barreto FC, Mendes M, et al. Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease. Kidney Int. 2015;87(5):1039–1045.
   PubMed Web of Science ®Google Scholar
• Gong L, Zheng D, Yuan J, et al. Elevated levels of serum sclerostin are linked to adverse cardiovascular outcomes in peritoneal dialysis patients. Int Urol Nephrol. 2018;50(5):955–961.
   PubMed Web of Science ®Google Scholar
• Kundakci Gelir G, Sengul S, Nergizoglu G, et al. Is sclerostin level associated with cardiovascular diseases in hemodialysis patients? Blood Purif. 2018;46(2):118–125.
   PubMed Web of Science ®Google Scholar
• Jin S, Zhu M, Yan J, et al. Serum sclerostin level might be a potential biomarker for arterial stiffness in prevalent hemodialysis patients. Biomarkers Med. 2016;10(7):689–699.
   PubMed Web of Science ®Google Scholar
• Sutton-Tyrrell K, Najjar SS, Boudreau RM, et al. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation. 2005;111(25):3384–3390.
   PubMed Web of Science ®Google Scholar
• Brandenburg VM, Kramann R, Koos R, et al. Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: across-sectional study. BMC Nephrol. 2013;14(1):219.
   PubMedGoogle Scholar
• Qureshi AR, Olauson H, Witasp A, et al. Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int. 2015;88(6):1356–1364.
   PubMed Web of Science ®Google Scholar
• Pelletier S, Confavreux CB, Haesebaert J, et al. Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients? Osteoporos Int. 2015;26(8):2165–2174.
   PubMed Web of Science ®Google Scholar
• Lee YT, Ng HY, Chiu TT, et al. Association of bone-derived biomarkers with vascular calcification in chronic hemodialysis patients. Clin Chim Acta. 2016;452:38–43.
   PubMed Web of Science ®Google Scholar
• Wang XR, Yuan L, Zhang JJ, et al. Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3–5D. Nephrology (Carlton). 2017;22(4):286–292.
   PubMed Web of Science ®Google Scholar